MAS1 and fatty liver disease: It serves as a weak FXR agonist and may lead to ischemic biliary lesions.[34, 35] At 100 μm, it inhibits chenodeoxycholic acid (CDCA)‐induced FXR activation[36] and acts as an FXR antagonist in colon cancer and metabolic‐associated fatty liver disease.[37, 38, 39] Our research found that Mas1−/‐ mice showed a notable decrease in serum and fecal DCA levels along with activated hepatic FXR signaling.